Does the media prefer NKTR or ABVX?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Abivax. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Abivax. Abivax's average media sentiment score of 0.51 beat Nektar Therapeutics' score of 0.11 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PCVX or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Nektar Therapeutics' score of 0.11 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CYTK or NKTR?

In the previous week, Cytokinetics had 13 more articles in the media than Nektar Therapeutics. MarketBeat recorded 18 mentions for Cytokinetics and 5 mentions for Nektar Therapeutics. Cytokinetics' average media sentiment score of 0.42 beat Nektar Therapeutics' score of 0.11 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRAX or NKTR?

In the previous week, Nektar Therapeutics had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Nektar Therapeutics and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.75 beat Nektar Therapeutics' score of 0.11 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TGTX or NKTR?

In the previous week, TG Therapeutics had 7 more articles in the media than Nektar Therapeutics. MarketBeat recorded 12 mentions for TG Therapeutics and 5 mentions for Nektar Therapeutics. TG Therapeutics' average media sentiment score of 0.86 beat Nektar Therapeutics' score of 0.11 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Nektar Therapeutics (NKTR) Competitors

$67.10 -1.26 (-1.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$69.10 +2.00 (+2.98%)

As of 09/18/2026 07:58 PM Eastern

Compare

NKTR vs. ABVX, PCVX, CYTK, PRAX, and TGTX

Should you buy Nektar Therapeutics stock or one of its competitors? Nektar Therapeutics's main competitors and comparable companies include Abivax (ABVX), Vaxcyte (PCVX), Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nektar Therapeutics compare to Abivax?

Nektar Therapeutics (NASDAQ:NKTR) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Nektar Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Nektar Therapeutics had 1 more articles in the media than Abivax. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Abivax. Abivax's average media sentiment score of 0.51 beat Nektar Therapeutics' score of 0.11 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Abivax	N/A	-99.02%	-70.26%

Nektar Therapeutics currently has a consensus target price of $141.50, suggesting a potential upside of 110.88%. Abivax has a consensus target price of $156.38, suggesting a potential upside of 48.88%. Given Nektar Therapeutics' higher possible upside, research analysts plainly believe Nektar Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Abivax has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Nektar Therapeutics beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Nektar Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Vaxcyte has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Vaxcyte's return on equity of -37.56% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Nektar Therapeutics has higher revenue and earnings than Vaxcyte. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A

Vaxcyte has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vaxcyte currently has a consensus target price of $98.00, indicating a potential upside of 68.59%. Nektar Therapeutics has a consensus target price of $141.50, indicating a potential upside of 110.88%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Nektar Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.13 beat Nektar Therapeutics' score of 0.11 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nektar Therapeutics beats Vaxcyte on 9 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Nektar Therapeutics has a net margin of -287.84% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Cytokinetics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Nektar Therapeutics has lower revenue, but higher earnings than Cytokinetics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	97.21	-$784.96M	-$7.22	N/A
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A

Cytokinetics presently has a consensus price target of $103.37, indicating a potential upside of 50.29%. Nektar Therapeutics has a consensus price target of $141.50, indicating a potential upside of 110.88%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

75.9% of Nektar Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cytokinetics had 13 more articles in the media than Nektar Therapeutics. MarketBeat recorded 18 mentions for Cytokinetics and 5 mentions for Nektar Therapeutics. Cytokinetics' average media sentiment score of 0.42 beat Nektar Therapeutics' score of 0.11 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cytokinetics beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nektar Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	976.22	-$303.27M	-$12.93	N/A
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A

Praxis Precision Medicines presently has a consensus target price of $612.42, indicating a potential upside of 104.86%. Nektar Therapeutics has a consensus target price of $141.50, indicating a potential upside of 110.88%. Given Nektar Therapeutics' higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Nektar Therapeutics had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Nektar Therapeutics and 1 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.75 beat Nektar Therapeutics' score of 0.11 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -287.84%. Praxis Precision Medicines' return on equity of -34.15% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Summary

Praxis Precision Medicines beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

TG Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

TG Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 10.78%. Nektar Therapeutics has a consensus target price of $141.50, indicating a potential upside of 110.88%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, TG Therapeutics had 7 more articles in the media than Nektar Therapeutics. MarketBeat recorded 12 mentions for TG Therapeutics and 5 mentions for Nektar Therapeutics. TG Therapeutics' average media sentiment score of 0.86 beat Nektar Therapeutics' score of 0.11 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	14.12	$447.18M	$2.74	20.76
Nektar Therapeutics	$55.23M	41.48	-$164.08M	-$6.70	N/A

TG Therapeutics has a net margin of 55.22% compared to Nektar Therapeutics' net margin of -287.84%. TG Therapeutics' return on equity of 73.49% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

Summary

TG Therapeutics beats Nektar Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.29B	$3.89B	$7.24B	$13.21B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-10.01	14.23	275.49	25.40
Price / Sales	41.48	1,423.41	639.55	86.82
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	15.22	15.45	10.46	6.33
Net Income	-$164.08M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-3.81%	-1.21%	0.59%	1.12%
1 Month Performance	-9.97%	-3.29%	-1.74%	-2.39%
1 Year Performance	21.69%	37.74%	18.13%	5.35%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKTR Nektar Therapeutics	2.6469 of 5 stars	$67.10 -1.8%	$141.50 +110.9%	+21.7%	$2.29B	$55.23M	N/A	63	News Coverage Analyst Forecast High Trading Volume
ABVX Abivax	2.3252 of 5 stars	$102.23 -4.2%	$156.38 +53.0%	+27.6%	$8.92B	N/A	N/A	69	Upcoming Earnings
PCVX Vaxcyte	2.1343 of 5 stars	$58.77 -0.7%	$98.00 +66.8%	+83.1%	$8.74B	N/A	N/A	507	Positive News
CYTK Cytokinetics	2.893 of 5 stars	$69.39 +0.1%	$103.37 +49.0%	+41.3%	$8.63B	$88.04M	N/A	673	News Coverage Insider Trade
PRAX Praxis Precision Medicines	2.9264 of 5 stars	$308.99 -1.2%	$585.95 +89.6%	+608.1%	$8.63B	$8.55M	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. ABVX, PCVX, CYTK, PRAX, and TGTX

How does Nektar Therapeutics compare to Abivax?

Summary

How does Nektar Therapeutics compare to Vaxcyte?

Summary

How does Nektar Therapeutics compare to Cytokinetics?

Summary

How does Nektar Therapeutics compare to Praxis Precision Medicines?

Summary

How does Nektar Therapeutics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. ABVX, PCVX, CYTK, PRAX, and TGTX

How does Nektar Therapeutics compare to Abivax?

Which has better earnings & valuation, NKTR or ABVX?

Does the media prefer NKTR or ABVX?

Is NKTR or ABVX more profitable?

Do analysts prefer NKTR or ABVX?

Do insiders and institutionals have more ownership in NKTR or ABVX?

Which has more risk & volatility, NKTR or ABVX?

Summary

How does Nektar Therapeutics compare to Vaxcyte?

Is PCVX or NKTR more profitable?

Which has better valuation & earnings, PCVX or NKTR?

Which has more risk and volatility, PCVX or NKTR?

Do insiders & institutionals believe in PCVX or NKTR?

Do analysts prefer PCVX or NKTR?

Does the media refer more to PCVX or NKTR?

Summary

How does Nektar Therapeutics compare to Cytokinetics?

Is CYTK or NKTR more profitable?

Which has more volatility and risk, CYTK or NKTR?

Which has higher earnings and valuation, CYTK or NKTR?

Do analysts prefer CYTK or NKTR?

Do institutionals and insiders believe in CYTK or NKTR?

Does the media refer more to CYTK or NKTR?

Summary

How does Nektar Therapeutics compare to Praxis Precision Medicines?

Which has more volatility & risk, PRAX or NKTR?

Do institutionals & insiders believe in PRAX or NKTR?

Which has better earnings and valuation, PRAX or NKTR?

Do analysts prefer PRAX or NKTR?

Does the media favor PRAX or NKTR?

Is PRAX or NKTR more profitable?

Summary

How does Nektar Therapeutics compare to TG Therapeutics?

Which has more risk and volatility, TGTX or NKTR?

Do analysts recommend TGTX or NKTR?

Do institutionals & insiders believe in TGTX or NKTR?

Does the media favor TGTX or NKTR?

Which has preferable earnings and valuation, TGTX or NKTR?

Is TGTX or NKTR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools